Skip to content

DNA Nanotechnology for Effective Cancer Immunotherapy

Aug 2026 · ACS Nano Medicine · 0 citations · 117 references

TL;DR

With continued advances in structural design, ligand functionalization, and immune engineering, DNA nanotechnology holds the potential to reshape cancer immunotherapy and pave the way for highly targeted, personalized, and effective treatments that outperform current clinical approaches in specificity, efficacy, and safety.

Abstract

Cancer immunotherapy has transformed oncological treatment by harnessing the immune system to target tumors. However, challenges such as drug resistance, poor immunogenicity, and inefficient antigen delivery limit its full potential. DNA nanotechnology offers a transformative solution through the development of programmable, biocompatible nanostructures capable of precise antigen presentation, codelivery of immunostimulatory agents, and modulation of the tumor microenvironment. DNA nanostructures, including origami, tetrahedra, and virus-like particles, enable multivalent display of tumor antigens, incorporation of adjuvants like CpG oligodeoxynucleotides, and encapsulation of therapeutic RNAs such as mRNA and siRNA. These features enhance antigen presentation, improve endosomal escape, and stimulate robust innate and adaptive immune responses. Moreover, bispecific DNA nanoconstructs can bridge immune effector cells with tumor cells, simulating immune synapses and enhancing cytotoxicity. The modularity and precision of DNA scaffolds also support patient-specific vaccine development, particularly when integrated with genomic sequencing and CRISPR-based neoantigen discovery. Virus-inspired DNA nanostructures further mimic native viral immunogenicity while allowing safer, customizable antigen loading. Future efforts should focus on overcoming translational barriers, including scalable manufacturing, in vivo stability, and regulatory standardization. With continued advances in structural design, ligand functionalization, and immune engineering, DNA nanotechnology holds the potential to reshape cancer immunotherapy. It paves the way for highly targeted, personalized, and effective treatments that outperform current clinical approaches in specificity, efficacy, and safety.

View source

Similar papers

Review Open access Oct 2026

Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.

Nanotechnology has transformed vaccine development by engineering nanovaccines that offer precise control over antigen performance, immune modulation and targeted delivery. These platforms influence physicochemical properties size, charge, and ligand expression to direct antigen trafficking, co-deliver adjuvants and an...

Muhammad Inam, Muhammad Jamshed, Abuzar Osman · 0 citations
Review Open access Sep 2026

Engineered Bacteriophages in Cancer Immunotherapy: Emerging Concepts and Potential Integration with CAR-T Cell Therapy.

Due to antigen heterogeneity, restricted immune cell trafficking and an immunosuppressive, nutrient-restricted tumour microenvironment, solid tumours remain resistant to modern immunotherapies. Engineered bacteriophages offer a modular framework to overcome these obstacles: programmable virus-like particles with scalab...

J. Alrahimi · 0 citations
Aug 2026

Self-assembled protein-aptamer nanoparticles for targeted cancer immunotherapy.

This study proposes a controllable in situ self-assembly strategy to construct FimH protein-based nanoparticles incorporating mIFP protein and PD-L1 aptamer, demonstrating potential for targeted protein delivery and tumor therapy.

Xuemei Wang, Shengbo Li, Tian Wang et al. · 0 citations
#gene editing Review Aug 2026

Microneedle-mediated delivery of DNA and mRNA therapeutics for cancer immunotherapy: advances, design strategies and translational challenges

Rather than treating MNs as a universal replacement for systemic delivery, this review position them as a route-specific platform whose clinical value will depend on rational cargodevice matching, standardized potency testing, and validation in translational models.

Haowei Liu, Qiong Yi, Ling Mei et al. · 0 citations
Aug 2026

Dual delivery of immunostimulatory oligonucleotides and doxorubicin by magnetic nanoparticles and metal-organic frameworks for antitumor immunotherapy.

The immunosuppressive tumor microenvironment (TME) remains a major challenge to effective cancer immunotherapy. We hypothesized that combining dendritic cell (DC) maturation with immunogenic cell death (ICD) could enhance antitumor immunity by simultaneously providing immune-activating signals and tumor-associated anti...

Jaesung Lim, H. Seo, Jun-Hyeok Han et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.